Clinical Trials Logo

Obsessive-Compulsive Disorder clinical trials

View clinical trials related to Obsessive-Compulsive Disorder.

Filter by:

NCT ID: NCT00251303 Completed - Clinical trials for Autism Spectrum Disorder

Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders

Start date: August 2005
Phase: Phase 2
Study type: Interventional

This study will examine the effectiveness of riluzole for treating Obsessive-Compulsive Disorder in Youth, Including those with Autism Spectrum Disorders.

NCT ID: NCT00234689 Completed - Clinical trials for Obsessive Compulsive Disorder

Efficacy of Naltrexone Treatment as Augmentation to SSRI in OCD Patients

Start date: January 2002
Phase: N/A
Study type: Interventional

Assessing the efficacy of Naltrexone as augmentation to SSRI in patients with OCD

NCT ID: NCT00229385 Completed - Schizophrenia Clinical Trials

Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD)

Start date: January 2006
Phase: N/A
Study type: Interventional

Comparing schizophrenic patients with comorbid OCD and schizophrenic patients without OCD in response to Ziprasidone and in cognitive functioning as compared with OCD patients

NCT ID: NCT00229320 Completed - Clinical trials for Obsessive Compulsive Disorder

Short Term Group Therapy for OCD

Start date: February 2005
Phase: N/A
Study type: Interventional

Assessing OCD before and after group therapy

NCT ID: NCT00216294 Completed - Clinical trials for Obsessive Compulsive Disorder (OCD)

Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder

Start date: February 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and tolerability of RG1068 (Synthetic Human Secretin) when administered three times weekly to outpatients with obsessive compulsive disorder (OCD), to determine the impact of multiple subcutaneous injections of RG1068 on the symptoms of OCD, as measured by changes in clinical scales, and to evaluate the effect of RG1068 on OCD patients' anxiety, quality of life, and depression.

NCT ID: NCT00215137 Completed - OCD Clinical Trials

Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder

Start date: October 2004
Phase: Phase 2
Study type: Interventional

This study will determine the safety and effectiveness of escitalopram (Lexapro)in treating obsessive-compulsive disorder (OCD) symptoms.

NCT ID: NCT00211744 Completed - Clinical trials for Obsessive-compulsive Disorder

Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder

Start date: August 2004
Phase: Phase 4
Study type: Interventional

A 12-week program to examine the effectiveness of topiramate in adjunctive treatment for adults with obsessive-compulsive disorder and who are currently on serotonin reuptake inhibitor medications (ages 18-65).

NCT ID: NCT00187928 Completed - Clinical trials for Obsessive-Compulsive Disorder

Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder

Start date: January 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if a drug called topiramate is safe and effective as an add-on therapy in the treatment of Obsessive-Compulsive Disorder (OCD). Topiramate is an investigational drug for OCD, which means it has not been approved by the U.S. Food and Drug Administration (FDA). Topiramate has been approved as an add-on therapy for adults and children with partial onset seizures or generalized tonic-clonic seizures, and for patients 2 years of age and older with a severe form of epilepsy called Lennox-Gastaut Syndrome. Up to 96 subjects will be enrolled in this study. This study consists of three phases: Washout/Screening Phase, Double-Blind Phase, and Taper Phase. The total expected length of your participation in the study is approximately four months.

NCT ID: NCT00184262 Completed - Clinical trials for Obsessive-Compulsive Disorder

Exposure and Response Prevention With Behavioral- Versus Cognitive Therapy Rationale in Obsessive Compulsive Disorder

Start date: January 2003
Phase: N/A
Study type: Interventional

The aim of the study is to determine whether exposure and response prevention (ERP) is more effective when patients are presented with a behavioral therapy versus cognitive therapy rationale in the treatment of obsessive-compulsive disorder (OCD).

NCT ID: NCT00182520 Completed - Clinical trials for Obsessive Compulsive Disorder

Efficacy of Adding Topiramate to Current Treatment in Refractory Obsessive Compulsive Disorder (OCD)

Start date: January 2002
Phase: Phase 4
Study type: Interventional

SRI's are considered first-line treatments for OCD, however many patients continue to have significant symptoms despite an adequate trial of an SRI. Neuroimaging studies have shown that the glutamate neurological system is involved in OCD. This study will test the safety and efficacy of topiramate, a drug, which targets glutamate, in the treatment of OCD, where the OCD has been un-responsive, or partially responsive to regular SRI treatment.